1-6 of 6
Stéphan Vagner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Isabelle Girault, Julien Adam, Shensi Shen, Séverine Roy, Caroline Brard, Sara Faouzi, Emilie Routier, Jéremy Lupu, Sarah Warren, Kristina Sorg, SuFey Ong, Pascale Morel, Jean-Yves Scoazec, Stéphan Vagner, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 518–525.
https://doi.org/10.1158/1078-0432.CCR-21-1229
Published: 01 February 2022
View article titled, A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Open the PDF for A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer

Marine F. Garrido, Nicolas J.-P. Martin, Matthieu Bertrand, Catherine Gaudin, Frédéric Commo, Nassif El Kalaany, Nader Al Nakouzi, Ladan Fazli, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Daniel Compagno, Martin Gleave, Yohann Loriot, Laurent Désaubry, Stéphan Vagner, Karim Fizazi, Anne Chauchereau
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 710–723.
https://doi.org/10.1158/1078-0432.CCR-18-0704
Published: 15 January 2019
View article titled, Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Open the PDF for Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment

Hélène Malka-Mahieu, Michelle Newman, Laurent Désaubry, Caroline Robert, Stéphan Vagner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 21–25.
https://doi.org/10.1158/1078-0432.CCR-14-2362
Published: 02 January 2017
View article titled, Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Open the PDF for Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment in another window
Includes: Supplementary data
Journal Articles

Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies

Lise Boussemart, Helene Malka-Mahieu, Isabelle Girault, Delphine Allard, Oskar Hemmingson, Nyam Kamsu-Kom, Sandrine Agoussi, Alexander Eggermont, Laurent Desaubry, Caroline Robert, Stephan Vagner
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): A23.
https://doi.org/10.1158/1557-3265.PMS14-A23
Published: 13 February 2015
View article titled, Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies
Journal Articles

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussemart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druillennec, Stephan Vagner, Alain Eychène, Nicolas Dumaz, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 263–272.
https://doi.org/10.1158/1078-0432.CCR-11-1344
Published: 02 January 2012
View article titled, Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <em>HRAS</em>, <em>TP53</em>, and <em>TGFBR1</em>
Open the PDF for Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <em>HRAS</em>, <em>TP53</em>, and <em>TGFBR1</em> in another window
Includes: Supplementary data
Journal Articles

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

Luc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, Ken André Olaussen, Stephan Vagner, Julien Adam, Aïcha Goubar, Nicolas Dorvault, Vladimir Lazar, Bastien Job, Benjamin Besse, Pierre Validire, Philippe Girard, Ludovic Lacroix, Johanna Hasmats, Fabienne Dufour, Fabrice André, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5562–5572.
https://doi.org/10.1158/1078-0432.CCR-11-0790
Published: 01 September 2011
View article titled, Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
Open the PDF for Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC in another window
Includes: Supplementary data